-
2024-515349-41-00
4
2025-07-29
Metastatic Breast Cancer HR+, HER2-
-
2024-517987-46-00
4
2025-07-21
Essential tremor
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2023-504831-42-00
5
2025-06-27
patient with colorectal cancer with hepatic metastasis
-
2024-517325-43-00
4
2025-06-19
multiple myeloma
-
2024-517996-19-00
4
2025-06-19
Primary premature ejaculation
-
2023-509788-25-00
6
2025-06-16
Rheumatoid arthritis
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2023-509391-42-00
11
2025-06-02
Chron's Disease
-
2023-506935-14-01
5
2025-06-01
Ischemic stroke
-
2024-516650-22-00
6
2025-05-16
Renal carcinoma
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-511495-32-00
5
2025-04-16
Chronic Phase Chronic Myeloid Leukemia
-
2024-513053-69-00
5
2025-04-16
Moderately to Severely Active Crohn's Disease (CD)
-
2024-513084-38-00
9
2025-04-15
Recently diagnosed non favorable Acute Myeloid Leukemias
-
2023-504086-23-00
5
2025-03-27
Subjects with PBC with a non-optimal response to UDCA.
-
2024-512729-10-00
4
2025-03-27
Recurrent or metastatic solid cancer harboring a FGFR1,2 ,3 fusion/rea
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2023-505291-30-01
4
2025-03-06
Triple Negative Breast Cancer with residual disease after neoadjuvant
-
2023-507873-16-00
11
2025-03-04
1st line treatment for unresectable metastatic colorectal cancer
-
2023-510292-65-00
5
2025-02-25
chronic graft-versus-host disease
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-504554-35-00
5
2025-01-17
incisional hernia
-
2023-509963-25-00
4
2025-01-17
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer